Avantor lifts 2026 outlook as VWR returns to growth
Second-quarter results beat estimates, but Avantor’s Bioscience & Medtech Products segment remained in decline as management looked toward a second-half recovery.
Makkler Newsroom · Oct 13, 06:55 PM · 1 min read